Puma Biotechnology reports Q3 EPS 46c, consensus 35c

Reports Q3 revenue $80.5M, consensus $70.7M. “We are pleased to announce both positive net income and positive operating cash flow for the third quarter of 2024,” said Alan H. Auerbach, CEO. “In addition to our focus on the commercialization of NERLYNX, we are also continuing to make progress with the clinical development of alisertib for patients with extensive stage small cell lung cancer and patients with chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer. We anticipate the following key milestones over the next 12 months: (i) initiation of ALI-1201/ALISCA(TM)-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer (Q4 2024); (ii) presentation of interim data from ALI-4201/ALISCA(TM)-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (2025); and (iii) presentation of interim data from ALISCA(TM)-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer (2025).”